Correlation of dopamine transporter imaging with parkinsonian motor handicap: How close is it?
Author:
- 1 October 2003
- journal article
- research article
- Published by Wiley in Movement Disorders
- Vol. 18 (S7) , S43-S51
Abstract
During the past decade, dopamine transporter (DAT) imaging with single photon emission computerized tomography (SPECT) or positron emission tomography (PET) has evolved as an objective in vivo marker of nigrostriatal neuron loss in Parkinson's disease (PD). We investigate the relationship between striatal DAT binding, measured with [123I]β‐CIT SPECT, and parkinsonian motor handicap in a sample of 59 PD patients with minimal to severe disability, and review published cross‐sectional studies on the correlation between DAT imaging and motor symptoms in PD. Earlier studies as well as the present results show a good correlation between overall striatal DAT binding and global measures of disease severity such as the Hoehn and Yahr scale, the total score on the Unified Parkinson's Disease Rating Scale (UPDRS), and UPDRS activities of daily living, with a progressive decline of DAT binding with increasing disability. A number of studies found a significant inverse correlation of striatal DAT binding with UPDRS motor score. Bradykinesia, posture, gait, and other midline symptoms, such as speech and facial expression, compared with rigidity, seem to be more closely related to striatal DAT binding. By contrast, neither the severity of parkinsonian rest nor of action tremor is related to the degree of dopaminergic denervation as measured by DAT imaging. Motor symptoms in the clinically less affected body side show a closer correlation with striatal DAT binding than do symptoms occurring in the dominantly affected body side. The correlation of putamen and caudate DAT binding with parkinsonian motor handicap seems to be similar. Although there have been limited comparative studies applying [18F]fluorodopa PET and DAT imaging in the same group of PD patients, available data suggest that putamen [18F]fluorodopa uptake, when compared with striatal DAT binding, may be more closely related to parkinsonian motor handicap. © 2003 Movement Disorder SocietyKeywords
This publication has 33 references indexed in Scilit:
- Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease ProgressionJAMA, 2002
- Progression of dopaminergic degeneration in Parkinson's disease and atypical parkinsonism: A longitudinal β‐CIT SPECT studyMovement Disorders, 2001
- Progression in Parkinson's disease: A positron emission tomography study with a dopamine transporter ligand [18F]CFTAnnals of Neurology, 2000
- Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT1997
- Presynaptic monoaminergic vesicles in Parkinson's disease and normal agingAnnals of Neurology, 1996
- An [18F]dopa–PET and clinical study of the rate of progression in Parkinson’s diseaseBrain, 1996
- Decreased single‐photon emission computed tomographic {123I}β‐CIT striatal uptake correlates with symptom severity in parkinson's diseaseAnnals of Neurology, 1995
- The Nigrostriatal Dopaminergic System Assessed In Vivo by Positron Emission Tomography in Healthy Volunteer Subjects and Patients With Parkinson's DiseaseArchives of Neurology, 1990
- Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsyAnnals of Neurology, 1990
- The metabolic anatomy of Parkinson's disease: Complementary [18F]fluorodeoxyglucose and [18F]fluorodopa positron emission tomographic studiesMovement Disorders, 1990